Braskem Past Earnings Performance
Past criteria checks 0/6
Braskem's earnings have been declining at an average annual rate of -5.3%, while the Chemicals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 8.5% per year.
Key information
-5.3%
Earnings growth rate
-5.3%
EPS growth rate
| Chemicals Industry Growth | 13.1% |
| Revenue growth rate | 8.5% |
| Return on equity | n/a |
| Net Margin | -12.9% |
| Next Earnings Update | 06 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Braskem makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 70,362 | -9,073 | 4,367 | 420 |
| 31 Mar 24 | 69,043 | -6,108 | 4,520 | 395 |
| 31 Dec 23 | 70,569 | -4,579 | 4,471 | 383 |
| 30 Sep 23 | 72,867 | -4,715 | 4,638 | 386 |
| 30 Jun 23 | 81,578 | -3,400 | 4,746 | 398 |
| 31 Mar 23 | 89,234 | -4,036 | 4,846 | 395 |
| 31 Dec 22 | 96,519 | -336 | 4,910 | 374 |
| 30 Sep 22 | 105,742 | 1,905 | 4,921 | 354 |
| 30 Jun 22 | 108,654 | 6,545 | 4,910 | 323 |
| 31 Mar 22 | 109,664 | 15,375 | 4,767 | 307 |
| 31 Dec 21 | 105,625 | 13,985 | 4,587 | 297 |
| 30 Sep 21 | 96,151 | 14,301 | 4,331 | 276 |
| 30 Jun 21 | 83,844 | 9,351 | 4,074 | 265 |
| 31 Mar 21 | 68,611 | -548 | 3,908 | 257 |
| 31 Dec 20 | 58,543 | -6,692 | 3,826 | 251 |
| 30 Sep 20 | 52,445 | -10,460 | 3,866 | 251 |
| 30 Jun 20 | 49,821 | -9,935 | 3,952 | 246 |
| 31 Mar 20 | 51,970 | -7,375 | 4,028 | 248 |
| 31 Dec 19 | 52,324 | -2,798 | 4,015 | 248 |
| 30 Sep 19 | 54,520 | 46 | 3,886 | 235 |
| 30 Jun 19 | 57,500 | 2,278 | 3,888 | 244 |
| 31 Mar 19 | 57,949 | 2,741 | 3,614 | 235 |
| 31 Dec 18 | 58,000 | 2,867 | 3,395 | 219 |
| 30 Sep 18 | 55,792 | 3,114 | 3,191 | 210 |
| 30 Jun 18 | 51,605 | 2,569 | 2,924 | 181 |
| 31 Mar 18 | 49,690 | 3,329 | 2,913 | 173 |
| 31 Dec 17 | 49,261 | 3,857 | 2,894 | 167 |
| 30 Sep 17 | 48,678 | 1,153 | 2,835 | 153 |
| 30 Jun 17 | 48,498 | 1,238 | 2,781 | 152 |
| 31 Mar 17 | 48,349 | 548 | 2,754 | 153 |
| 31 Dec 16 | 47,664 | -438 | 2,689 | 162 |
| 30 Sep 16 | 47,547 | 2,188 | 2,563 | 170 |
| 30 Jun 16 | 48,729 | 2,870 | 2,480 | 170 |
| 31 Mar 16 | 48,599 | 3,556 | 2,397 | 172 |
| 31 Dec 15 | 46,880 | 2,995 | 2,173 | 170 |
| 30 Sep 15 | 46,562 | 2,965 | 2,384 | 157 |
| 30 Jun 15 | 45,123 | 1,667 | 2,369 | 154 |
| 31 Mar 15 | 44,384 | 710 | 2,380 | 144 |
| 31 Dec 14 | 46,031 | 864 | 2,366 | 138 |
| 30 Sep 14 | 45,203 | 812 | 2,259 | 138 |
| 30 Jun 14 | 44,417 | 942 | 2,196 | 132 |
| 31 Mar 14 | 43,311 | 699 | 2,118 | 125 |
| 31 Dec 13 | 40,969 | 510 | 2,079 | 116 |
| 30 Sep 13 | 40,065 | 467 | 2,163 | 106 |
Quality Earnings: BAK N is currently unprofitable.
Growing Profit Margin: BAK N is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BAK N is unprofitable, and losses have increased over the past 5 years at a rate of 5.3% per year.
Accelerating Growth: Unable to compare BAK N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BAK N is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-6.6%).
Return on Equity
High ROE: BAK N's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.